<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00554463</url>
  </required_header>
  <id_info>
    <org_study_id>RTOG 0623</org_study_id>
    <secondary_id>CDR0000574000</secondary_id>
    <secondary_id>NCI-2009-00742</secondary_id>
    <nct_id>NCT00554463</nct_id>
  </id_info>
  <brief_title>G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer</brief_title>
  <official_title>A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer and Leukemia Group B</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radiation Therapy Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cisplatin and etoposide, work in different
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
      dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Colony-stimulating
      factors, such as G-CSF or pegfilgrastim, may increase the number of immune cells found in
      bone marrow or peripheral blood and may help the immune system recover from the side effects
      of chemotherapy and radiation therapy.

      PURPOSE: This phase II trial is studying G-CSF and pegfilgrastim to see how well they work in
      treating neutropenia in patients undergoing combination chemotherapy and radiation therapy
      for limited stage small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To evaluate the safety and efficacy of filgrastim (G-CSF) in reducing grade 4
           neutropenia or grades 3-4 febrile neutropenia in patients with limited stage small cell
           lung cancer treated with radiotherapy and concurrent chemotherapy comprising cisplatin
           and etoposide.

      Secondary

        -  To evaluate the safety and efficacy of pegfilgrastim in reducing grade 4 neutropenia or
           grades 3-4 febrile neutropenia in patients treated with adjuvant chemotherapy comprising
           cisplatin and etoposide.

        -  To estimate the incidence of dose modifications or treatment delays in patients treated
           with this regimen.

        -  To estimate the incidence of esophagitis, pneumonitis, and other non-hematological
           adverse events in patients treated with this regimen.

        -  To estimate the incidence of grade 4 thrombocytopenia in patients treated with this
           regimen.

        -  To estimate the median and two-year rate of progression-free and overall survival of
           patients treated with this regimen.

      OUTLINE: This is a multicenter study.

      Patients undergo thoracic radiotherapy once daily on days 1-5 of weeks 1-3 and twice daily on
      days 1-5 of weeks 4 and 5 for a total of 16 fractions. Patients also receive concurrent
      chemotherapy comprising cisplatin IV on day 1 and etoposide IV on days 1-3. Chemotherapy
      repeats every 3 weeks for 2 courses. Patients receive filgrastim (G-CSF) subcutaneously (SC)
      on days 4-13 and 25-34.

      After completion of chemoradiotherapy, patients receive adjuvant chemotherapy comprising
      cisplatin IV on day 1 and etoposide IV on days 2 and 3. Adjuvant therapy repeats every 21
      days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
      Patients also receive pegfilgrastim SC on day 4 of each course of adjuvant therapy.

      After completion of study therapy, patients are followed every 3 months for one year, every 6
      months for 2-3 years, and then annually for up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Grade 4 Neutropenia or Grades 3-4 Febrile Neutropenia Episodes During Concurrent Chemoradiotherapy as Assessed by NCI CTCAE v 3.0 (Common Terminology Criteria for Adverse Events)</measure>
    <time_frame>At the completion of all treatment, approximately 80 days</time_frame>
    <description>This study stopped accrual early with 5 accrued out of 44 planned, therefore no analyses were performed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade 4 Neutropenia or Grades 3-4 Febrile Neutropenia Episodes During Adjuvant Chemotherapy as Assessed by NCI CTCAE v 3.0</measure>
    <time_frame>At the completion of all treatment, approximately 80 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Dose Modifications or Treatment Delays</measure>
    <time_frame>At the completion of all treatment, approximately 80 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Esophagitis, Pneumonitis, and Other Non-hematological Adverse Events as Assessed by NCI CTCAE v 3.0</measure>
    <time_frame>At the completion of all treatment, approximately 80 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade 4 Thrombocytopenia</measure>
    <time_frame>At the completion of all treatment, approximately 80 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median and 2-year Rates of Progression-free and Overall Survival</measure>
    <time_frame>After all patients have been potentially followed for 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Combined Modality Therapy with Growth Factor Support</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation therapy, concurrent chemotherapy and Filgrastim followed by adjuvant chemotherapy and Pegfilgrastim</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>5mcg/kg/day subcutaneously on days 4-13 and 25-34 after each concurrent chemotherapy cycle for a total of 20 doses.</description>
    <arm_group_label>Combined Modality Therapy with Growth Factor Support</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <description>6 mg subcutaneously on day 4 of each adjuvant chemotherapy cycle.</description>
    <arm_group_label>Combined Modality Therapy with Growth Factor Support</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concurrent chemotherapy</intervention_name>
    <description>Beginning day 1 of radiation threapy (+/- 24 hours), repeat cycle every 3 weeks for two cycles:
Day 1: Cisplatin, 60 mg/m^2 i.v.; Days 1-3: Etoposide, 120 mg/m^2 i.v.</description>
    <arm_group_label>Combined Modality Therapy with Growth Factor Support</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant chemotherapy</intervention_name>
    <description>Cycle 1: Day 43: Cisplatin, 60 mg/m^2 i.v. and Etoposide, 120 mg/m^2 i.v.; Days 44 &amp; 45: Etoposide, 120 mg/m^2 i.v.
Cycle 2: Day 64: Cisplatin, 60 mg/m^2 i.v. and Etoposide, 120 mg/m^2; Days 65 &amp; 66: Etoposide, 120 mg/m^2 i.v.</description>
    <arm_group_label>Combined Modality Therapy with Growth Factor Support</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>A total of 61.2 Gy in 5 weeks: 1.8 Gy daily x 5 week, for 3 weeks (days 1-16); 1.8 Gy, BID, in 4th week (days 17-20) with off cord boost in p.m.; Off-cord boost, 1.8 Gy BID, in 5th week (days 21-25).</description>
    <arm_group_label>Combined Modality Therapy with Growth Factor Support</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed small cell carcinoma of the lung

               -  Limited stage disease, defined as any of the following:

                    -  Tumor confined to one hemithorax

                    -  T4 tumor not based on malignant pleural effusion

                    -  N3 disease not based on contralateral supraclavicular involvement

          -  No complete tumor resection

          -  Measurable or evaluable disease

          -  Pleural effusion allowed provided the following conditions are present:

               -  Effusion is too small to tap under CT guidance and is not evident on chest x-ray

               -  Effusion appears only after a thoracotomy or other invasive procedure

          -  Must have certification by a Radiation Oncologist that the tumor can be encompassed by
             limited radiotherapy fields without significantly compromising pulmonary function

          -  No distant metastases

        PATIENT CHARACTERISTICS:

          -  Zubrod performance status 0-1

          -  ANC (absolute neutrophil count) ≥ 1,800 cells/mm³

          -  Platelet count ≥ 100,000 cells/mm³

          -  Hemoglobin ≥ 10.0 g/dL (transfusion or other intervention to achieve hemoglobin ≥ 8.0
             g/dL allowed)

          -  Total bilirubin ≤ 1.5 mg/dL

          -  AST (aspartate aminotransferase) or ALT (alanine amino transferase ) ≤ 2 times the
             upper limit of normal (ULN)

          -  Alkaline phosphatase &lt; 2.5 times ULN (&lt; 5 times ULN if judged by the investigator to
             be related to liver metastases)

          -  Serum creatinine ≤ 1.5 mg/dL

          -  Creatinine clearance ≥ 50 mL/min

          -  FEV1 (Forced Expiratory Volume) obtained pre- or post-bronchodilator must be ≥ 1.5
             liters/second

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for ≥ 60 days after the
             last study treatment

          -  No prior invasive malignancy, except non-melanomatous skin cancer or other
             micro-invasive malignancy, or carcinoma in situ of the breast, oral cavity, or cervix,
             unless the patient has been disease-free for a minimum of 3 years

          -  No weight loss &gt; 5% for any reason within the past 3 months

          -  No severe, active comorbidity, defined as follows:

               -  Unstable angina and/or congestive heart failure requiring hospitalization within
                  the past 6 months

               -  Transmural myocardial infarction within the past 6 months

               -  Acute bacterial or fungal infection requiring intravenous antibiotics

               -  Chronic Obstructive Pulmonary Disease exacerbation with FEV1 (forced expiratory
                  volume) &lt; 1.5 liters/second or other respiratory illness requiring
                  hospitalization or precluding study therapy within the past 30 days

               -  Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects

               -  AIDS (HIV testing not required for entry into this protocol)

          -  No prior allergic reaction to the study drugs

        PRIOR CONCURRENT THERAPY:

          -  No prior systemic chemotherapy for lung cancer

               -  Prior chemotherapy for a different cancer is allowed, provided it was completed ≥
                  5 years prior to registration

          -  No prior radiotherapy to the region of the study cancer that would result in overlap
             of radiotherapy fields

          -  No concurrent intensity-modulated radiotherapy

          -  No concurrent amifostine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rogerio C. Lilenbaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai Comprehensive Cancer Center at Mount Sinai Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ritsuko U. Komaki, MD, FACR</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael A. Samuels, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CCOP - Mount Sinai Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Crawford, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida Shands Cancer Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucille P. Markey Cancer Center at University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Rockies Radiation Oncology Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Estabrook Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McDowell Cancer Center at Akron General Medical Center</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summa Center for Cancer Care at Akron City Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44309-2090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles M. Barrett Cancer Center at University Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research UK Medical Oncology Unit at Churchill Hospital &amp; Weatherall Institute of Molecular Medicine - Oxford</name>
      <address>
        <city>Salem</city>
        <state>Ohio</state>
        <zip>44460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Center</name>
      <address>
        <city>Wooster</city>
        <state>Ohio</state>
        <zip>44691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19612-6052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Milwaukee</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lilenbaum R, Samuels M, Taffaro-Neskey M, et al.: Phase II trial of combined modality therapy (cmt) with myeloid growth factors in patients with locally advanced non-small cell lung cancer (NSCLC). [Abstract] J Clin Oncol 26 (Suppl 15): A-7567, 2008.</citation>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2007</study_first_submitted>
  <study_first_submitted_qc>November 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2007</study_first_posted>
  <results_first_submitted>September 23, 2014</results_first_submitted>
  <results_first_submitted_qc>September 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 29, 2014</results_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>limited stage small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Combined Modality Therapy With Growth Factor Support</title>
          <description>Radiation therapy, concurrent chemotherapy and Filgrastim followed by adjuvant chemotherapy and Pegfilgrastim</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5">Subjects contributing data to the primary analysis are considered to have completed the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All eligible patients.</population>
      <group_list>
        <group group_id="B1">
          <title>Combined Modality Therapy With Growth Factor Support</title>
          <description>Radiation therapy, concurrent chemotherapy and Filgrastim followed by adjuvant chemotherapy and Pegfilgrastim</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" lower_limit="60" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Grade 4 Neutropenia or Grades 3-4 Febrile Neutropenia Episodes During Concurrent Chemoradiotherapy as Assessed by NCI CTCAE v 3.0 (Common Terminology Criteria for Adverse Events)</title>
        <description>This study stopped accrual early with 5 accrued out of 44 planned, therefore no analyses were performed.</description>
        <time_frame>At the completion of all treatment, approximately 80 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combined Modality Therapy With Growth Factor Support</title>
            <description>Radiation therapy, concurrent chemotherapy and Filgrastim followed by adjuvant chemotherapy and Pegfilgrastim</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grade 4 Neutropenia or Grades 3-4 Febrile Neutropenia Episodes During Concurrent Chemoradiotherapy as Assessed by NCI CTCAE v 3.0 (Common Terminology Criteria for Adverse Events)</title>
          <description>This study stopped accrual early with 5 accrued out of 44 planned, therefore no analyses were performed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Grade 4 Neutropenia or Grades 3-4 Febrile Neutropenia Episodes During Adjuvant Chemotherapy as Assessed by NCI CTCAE v 3.0</title>
        <time_frame>At the completion of all treatment, approximately 80 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Dose Modifications or Treatment Delays</title>
        <time_frame>At the completion of all treatment, approximately 80 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Esophagitis, Pneumonitis, and Other Non-hematological Adverse Events as Assessed by NCI CTCAE v 3.0</title>
        <time_frame>At the completion of all treatment, approximately 80 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Grade 4 Thrombocytopenia</title>
        <time_frame>At the completion of all treatment, approximately 80 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median and 2-year Rates of Progression-free and Overall Survival</title>
        <time_frame>After all patients have been potentially followed for 2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Subjects experiencing more than one of a given SAE (serious adverse event) are counted only once for that SAE. The same methodology was applied for non-serious adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Combined Modality Therapy With Growth Factor Support</title>
          <description>Radiation therapy, concurrent chemotherapy and Filgrastim followed by adjuvant chemotherapy and Pegfilgrastim</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis [with Grade 3-4 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological disorder NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Salivary gland disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis [with Grade 3-4 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sepsis [with unknown ANC]</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study stopped accrual early due to unmet targeted accrual goals, therefore no analyses were performed. The small number of patients would not have provided meaningful results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Wendy Seiferheld</name_or_title>
      <organization>NRG Onocology</organization>
      <email>wseiferheld@nrgonology.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

